(MedPage Today) — The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is becoming increasingly complex, with decisions now shaped by ESR1 and PIK3CA mutations, CDK4/6 inhibitor exposure…
Source link : https://www.medpagetoday.com/meetingcoverage/esmovideopearls/118577
Author :
Publish date : 2025-11-18 17:20:00
Copyright for syndicated content belongs to the linked Source.
